ArticleOpen forum infectious diseases2022
Approaching 65 Years: Is It Time to Consider Retirement of Vancomycin for Treating Methicillin-Resistant
Article in Open forum infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 25 citations in OpenAlex.
- From structural heart lesions to host burden: changing epidemiology and outcomes of native valve infective endocarditis, a nationwide study, 2006-2023.Open heart · 2026Article
- Next-generation hybrid bioanalytical platforms and clinical integration of TDM technologies for precision monitoring to optimize last-resort antibiotic therapy.Frontiers in pharmacology · 2026Review
- Overcoming Ceftaroline Resistance in MRSA Using Ceftaroline-Carbapenem Combination Therapy.Open forum infectious diseases · 2026Article
- Article
- Vancomycin Sensitization inACS infectious diseases · 2025Article
- Development of a novel quantitative lateral flow assay for vancomycin for therapeutic drug monitoring.Scientific reports · 2025Article
- Rates of Acute Kidney Injury Utilizing Area Under the Concentration-Time Curve Versus Trough-Based Vancomycin Dosing Strategies in Patients With Obesity.Open forum infectious diseases · 2025Article
- Early initiation of ceftaroline-based combination therapy for methicillin-resistant Staphylococcus aureus bacteremia.Annals of clinical microbiology and antimicrobials · 2025Article
- Incidence and risk factors for musculoskeletal adverse effects associated with daptomycin in patients receiving outpatient parenteral antimicrobial therapy.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
- Phenotypic and genotypic characteristics of mecA - positive oxacillin-sensitive Staphylococcus aureus isolated from patients with bloodstream infection in a tertiary hospital in Southern Brazil.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Measuring beta-lactam minimum inhibitory concentrations inJournal of clinical microbiology · 2024Review
- Risk factors for therapeutic failure in adults with methicillin-resistantLe infezioni in medicina · 2024Article
- ESKAPEE pathogens newly released from biofilm residence by a targeted monoclonal are sensitized to killing by traditional antibiotics.Frontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vancomycin was introduced nearly 65 years ago and remains the standard antibiotic for serious methicillin-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.